Accordingly, the expression of some of the common insulin resistance-associated genes, including Vitamin D receptor (Vdr), was found to be reduced by treating cells with Rosiglitazone, which is normally used as an insulin-sensitising agent in T2D. The gene discussed is VDR; the disease is type 2 diabetes mellitus.